Browse > Article

The Role of Uteroglobin in the Immunomodulation of Nonsmall Cell Lung Cancer Cells  

Yoon, Jung Min (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University, College of Medicine)
Lim, Jae-Jun (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University, College of Medicine)
Yoo, Chul-Gyu (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University, College of Medicine)
Lee, Choon-Taek (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University, College of Medicine)
Han, Sung Koo (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University, College of Medicine)
Shim, Young-Soo (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University, College of Medicine)
Kim, Young Whan (Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine and Lung Institute of Medical Research Center, Seoul National University, College of Medicine)
Publication Information
Tuberculosis and Respiratory Diseases / v.57, no.4, 2004 , pp. 336-344 More about this Journal
Abstract
Background : Immunotherapy for cancer has not been successful because of several obstacles in tumor and its environment. Inappropriate secretions of cytokines and growth factors by tumors cause substantial changes in the immune responses against tumors, affording the tumors some degree of protection from immune attack. Uteroglobin (UG, Clara cell secretory protein) has been known to have anti-inflammatory, immunomodulatory and anti-cancer activities. However, in lung cancer cells, UG expression is decreased. This study investigated the role of UG in the immunomodulation of lung cancer. Methods : The UG protein was overexpressed by Adenovirus(Ad)-UG transduction in non-small cell lung cancer cell lines. The concentration of Prostaglandin $E_2$ ($PGE_2$) was measured by Enzyme Immunoassay (EIA). Peripheral blood mononuclear cells (PBMC) from whole blood were prepared with Ficoll. PBMC were cultured in RPMI 1640, supernatant of A549, or A549 with UG or NS-398. Concentration of Th 1 type and Th 2 type cytokines from PBMC were measured by ELISA. Results : UG suppressed $PGE_2$, Cyclooxygenase-2 (COX-2) product. Both Th1 type such as Interleukin-2 (IL-2), Interferon-${\gamma}$ (IFN-${\gamma}$) and Tumor necrosis factor-${\alpha}$ (TNF-${\alpha}$) and Th2 type cytokines such as IL-10 and Tumor growth factor-${\beta}$ (TGF-${\beta}$) were increased when PBMC were cultured with supernatant of non small lung cancer cells. UG and COX-2 inhibitor, NS-398 induced normal immune response of PBMC. Although Th 1 type cytokines were increased, Th 2 type cytokines were reduced by UG. Conclusion : UG suppressed PGE2, COX-2 product. Supernatant of NSCLC induced imbalance of immune response of PBMC. However, UG reversed this imbalance. These results suggest that UG may be used in the development of immunotherapy for lung cancer.
Keywords
Uteroglobin; Lung cancer; PBMC;
Citations & Related Records

Times Cited By SCOPUS : 2
연도 인용수 순위
1 Mukherjee AB, Kundu GC and Mantile-Selvaggi G. 5uan CJ Mandal AK Chaltopadrhyay s, et al. Uteroglobin: a novel cytokine? Cell Mol. Life Sci. 1999;55:771-87
2 Levin SW, Butler JD, Schumacher UK, Wingtman PD, Mukherjee AB. Uteroglobin inhibits phospholipase A2 activity. Life Sci. 1986;38:1813-9
3 Sheng H, Shao J, Morrow J D, Beauchamp R D, DuBois R N, Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 1998;58:362–6
4 Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois R N, Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93:705–16
5 Plescia O J, Smith A H, Grinwich K, Subversion of immune system by tumor cells and role of prostaglandins. Proc Natl AcAd Sci. USA 1975; 72:1848–51
6 Yamamura M, Modlin RL, Ohmen JD, Moy RL. Local expression of antiinflammatory cytokines in cancer. J Clin Invest. 1993;91:1005-10
7 Lee JC, Park KH, Han SJ, Yoo CG, Lee CT, Han SK, et al. Inhibitory effect of Ad- uteroglobin transduction on the growth of lung cancer cell lines. Cancer GeneTherapy. 2003;10:287-93
8 Hasturk S, Kemp B, Kalapurakal SK, Kurie JM, Hong WK, Lee JS. Expression of cyclooxygenase-1 and cyclooxygenase-2 in bronchial epithelium and nonsmall cell lung carcinoma. Cancer. 2002;94:1023-31
9 Lala P K, Elkashab M, Kerbel R S, Parhar R S. Cure of human melanoma lung metastases in nude mice with chronic indomethacin therapy combined withmultiple rounds of IL-2: Characteristics of killer cells generated in situ. Int Immunol. 1990; 2:1149-58
10 Asselin-Paturel C, Echchakir H, Carayol G. Gay F, Opolon P, Grunerwald P. et al Quantitative analysis of Th1, Th2 and TGF-beta 1 cytokine expression in tumor, TIL and PBL of non-small cell lung cancer patients. Int J Cancer 1998; 77:7-12
11 Kambayashi T, Alexander HR, Fong M, Strassmann G. Potential involvement of IL-10 in suppressing tumor-associated macrophages. Colon-26-derivedprostaglandin E2 inhibits TNF-alpha release via a mechanism involving IL-10. J Immunol. 1995;154:3383-90
12 Leek RD, Lewis CE, Whitehouse R, Greenall M, Clarke J, Harris AL. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 1996;56:4625-9
13 Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D, Tarnawski AS. Prostaglandin E2 transactivates EGF receptor: a novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat Med. 2002;8:289-93
14 Strassmann G, Patil-Koota V, Finkelman F, Fong M, Kambayashi T. Evidence for the involvement of interleukin 10 in the differential deactivation of murine peritoneal macrophages by prostaglandin E2. J Exp Med. 1994;180:2365-70
15 Peri A, Cordella-Miele E, Miele L Mukherjee AB. Tissue-specific expression of the gene coding for human Clara cell 10-kD protein, a phospholipase A2-inhibitory protein. J Clin Invest 1993;92:2099-109
16 Smith D R, Kunkel SL, Burdick MD. Wuke CA, Owinger MB, Whyte RI, et al. Strieter. Production of Interleukin-10 by human bronchogenic carcinoma. Am J Pathol. 1994;145:18-25
17 Lee, P., M. Huang, J. Wang, S. Sharma and S. M. Dubinett. TGF-\beta specific antisense phosphorothioate oligonucleotides abrogate lung tumor-associated immunosuppression. J. Immunol. 1994;152:3222-30
18 Blaine SA, Wick M, Dessev C, Nemenoff RA. Induction of cPLA2 in lung epithelial cells and non-small cell lung cancer is mediated by Sp1 and c-Jun. J Biol Chem. 2001;276:42737-43
19 Tsujii M, DuBois R N, Alterations in cellular Adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995;83:493–501
20 Callejas NA, Casado M, Diaz-Guerra MJ, Bosca L, Martin-Sanz P. Expression of cyclooxygenase-2 promotes the release of matrix metalloproteinase-2 and -9 in fetal rat hepatocytes. Hepatology. 2001;33:860-7
21 Smyth GP, Stapleton PP, Barden CB, Mestre JR, Freeman TA, Duff MD, et al. Renal cell carcinoma induces prostaglandin E2 and T-helper type 2 cytokine production in peripheral blood mononuclear cells. Ann Surg Oncol. 2003; 10:455-62
22 Young MR, Wright MA, Matthews JP, Malik I, Prechel M. Suppression of T cell proliferation by tumor-induced granulocyte-macrophage progenitor cells producing transforming growth factor-beta and nitric oxide. J Immunol. 1996;156:1916-22
23 Mertens W C, Bramwell V H, Banerjee D, Gwardry-Sridhar F, Lala P K, et al. Sustained indomethacin and ranitidine with intermittent continuous infusion Interleukin-2 in advanced malignant melanoma: a phase Ⅱ study. Clin Oncol R coll Radiol 1993;5:107-13
24 Sharma S, Stolina M, Yang SC, Baratelli F, Lin JF, Dubinett SM. et al. Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res. 2003;9:961-8
25 van der Pouw Kraan TC, Boeije LC, Smeenk RJ, Wijdenes J, Aarden LA. Prostaglandin-E2 is a potent inhibitor of human interleukin 12 production. J ExpMed. 1995;181:775-9
26 Del Prete G, De Carli M, Ricci M, Romagnani S. Helper activity for immunoglobulin synthesis of T helper type 1 (Th1) and Th2 human T cell clones: the help of Th 1 clones is limited by their cytolytic capacity. J Exp Med 1991;174:809-13
27 Evans R. Macrophage requirement for growth of a murine fibrosarcoma. Br J Cancer 1978;37:1086-9
28 Mukherjee AB, Ulane RE, Agrawal AK. Role of uteroglobin and transglutaminase in masking the antigenicity of implanting rabbit embryos. Am J Reprod Immunol. 1982;2:135-41
29 Huang M, Wang J, Lee P, Sharma S, Mao JT, Meissner H, et al. Human non-small cell lung cancer cells express a type 2 cytokine pattern. Cancer Res. 1995;55:3847-53
30 Huang M., Sharma S., Mao J., T. And Dubinett S. M. Non-swall cell lung cancedr-derived soluble mediators and prostagladin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein production. J Immunol. 1996;157:5512-20
31 Ren Z, Pang G, Clancy R. Gastric carcinoma: T cell response and vascularity. Shift of the gastric T-cell response in gastric carcinoma. J Gastroenterol Hepatol 2001;16:142-8
32 Miele L, Cordella-Miele E, Mukherjee AB. Uteroglobin: structure, molecular biology, and new perspectives on its function as a phospholipase A2 inhibitor Endocr Rev. 1987:8:474-90
33 Alleva DG, Burger CJ, Elgert KD. Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10,TGF-beta, and prostaglandin E2. J Immunol. 1994;153:1674-86
34 Zhang Z, Zimonjic DB, Popsecu NC. Wang N, Geruard DS, Stone EM, et al. Human uteroglobin gene:structure, subchromosomal localization, and polymorphism. DNA Cell Biol. 1997;16:73-83
35 Funahashi A, Harland RW, LeFever A. Association of increased prostaglandin E2 content in bronchoalveolar lavage fluid and intrathoracic malignancy. Chest. 1994;106:166-72